Altering AAV tropism with mosaic viral capsids

被引:49
作者
Gigout, L
Rebollo, P
Clement, N
Warrington, KH
Muzyczka, N
Linden, RM
Weber, T
机构
[1] CUNY Mt Sinai Sch Med, Dept Gene & Cell Med, New York, NY 10029 USA
[2] CUNY Mt Sinai Sch Med, Dept Mol Cell & Dev Biol, New York, NY 10029 USA
[3] Univ Florida, Pediat Div Cellular & Mol Therapy, Alachua, FL 32615 USA
[4] Univ Florida, Coll Med, Powell Gene Therapy Ctr, Gainesville, FL 32610 USA
[5] Univ Florida, Coll Med, Dept Mol Genet & Microbiol, Gainesville, FL 32610 USA
关键词
D O I
10.1016/j.ymthe.2005.03.005
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Over the past decade, AAV-based vectors have emerged as promising candidates for gene therapeutic applications. Despite the broad tropism of the first eight serotypes identified, certain cell types are refractory to transduction with AAV-based vectors. Furthermore, for certain applications the targeting of specific cell types is desirable. To improve on present methods to alter AAV2 tropism, we take advantage of AAV2 mosaics. Here, we show that AAV2 mosaics have improved infectivity compared with all-mutant virions. Using an AAV2 mutant that contains the immunoglobulin-binding Z34C fragment of protein A, we demonstrate the utility of AAV2 mosaics to alter AAV2 tropism. This system allows us to transduce selectively and efficiently MO7e and Jurkat cells. The use of AAV2 mosaics with a protein A fragment inserted into their capsid, together with targeting antibodies, is a versatile method that allows the specific transduction of a wide array of cell types.
引用
收藏
页码:856 / 865
页数:10
相关论文
共 36 条
[1]   Transfer of contaminants in adeno-associated virus vector stocks can mimic transduction and lead to artifactual results [J].
Alexander, IE ;
Russell, DW ;
Miller, AD .
HUMAN GENE THERAPY, 1997, 8 (16) :1911-1920
[2]   Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab′γ)2 antibody [J].
Bartlett, JS ;
Kleinschmidt, J ;
Boucher, RC ;
Samulski, RJ .
NATURE BIOTECHNOLOGY, 1999, 17 (02) :181-186
[3]   CHARACTERIZATION OF ADENOVIRUS-ASSOCIATED VIRUS-INDUCED POLYPEPTIDES IN KB CELLS [J].
BULLER, RML ;
ROSE, JA .
JOURNAL OF VIROLOGY, 1978, 25 (01) :331-338
[4]   CELL-LINES FOR THE PRODUCTION OF RECOMBINANT ADENOASSOCIATED VIRUS [J].
CLARK, KR ;
VOULGAROPOULOU, F ;
FRALEY, DM ;
JOHNSON, PR .
HUMAN GENE THERAPY, 1995, 6 (10) :1329-1341
[5]  
Clark KR, 1996, GENE THER, V3, P1124
[6]   Clades of Adeno-associated viruses are widely disseminated in human tissues [J].
Gao, GP ;
Vandenberghe, LH ;
Alvira, MR ;
Lu, Y ;
Calcedo, R ;
Zhou, XY ;
Wilson, JA .
JOURNAL OF VIROLOGY, 2004, 78 (12) :6381-6388
[7]   Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2 [J].
Girod, A ;
Ried, M ;
Wobus, C ;
Lahm, H ;
Leike, K ;
Kleinschmidt, J ;
Deléage, G ;
Hallek, M .
NATURE MEDICINE, 1999, 5 (09) :1052-1056
[8]   Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids [J].
Grifman, M ;
Trepel, M ;
Speece, P ;
Gilbert, LB ;
Arap, W ;
Pasqualini, R ;
Weitzman, MD .
MOLECULAR THERAPY, 2001, 3 (06) :964-975
[9]   Novel tools for production and purification of recombinant adenoassociated virus vectors [J].
Grimm, D ;
Kern, A ;
Rittner, K ;
Kleinschmidt, JA .
HUMAN GENE THERAPY, 1998, 9 (18) :2745-2760
[10]   Generation and characterization of chimeric recombinant AAV vectors [J].
Hauck, B ;
Chen, L ;
Xiao, WD .
MOLECULAR THERAPY, 2003, 7 (03) :419-425